Pioglitazone Use in Patients with Prediabetes and History of Stroke

Primary Indication and Evidence

The American Diabetes Association recommends that in patients with a history of stroke and evidence of insulin resistance and prediabetes, pioglitazone may be considered to lower the risk of stroke or myocardial infarction, but this benefit must be balanced against increased risks of weight gain, edema, and fracture 1
Pioglitazone reduced the risk of stroke or myocardial infarction compared with placebo in patients with prior stroke and insulin resistance, with a 24% relative risk reduction in stroke or myocardial infarction (9.0% vs 11.8%) in the IRIS trial 2
Post hoc analysis showed a 29% relative risk reduction in acute coronary syndrome and 38% reduction in myocardial infarction 2

Pioglitazone increases heart failure risk through sodium retention at the distal nephron, particularly at higher doses and when combined with insulin 2
The hazard ratio of 1.8 for heart failure in patients receiving pioglitazone compared to sulfonylureas indicates a significant increased risk 3
Before prescribing pioglitazone, a pre-treatment cardiac assessment is required to ascertain history of heart failure, previous myocardial infarction, significant aortic or mitral valve disease, current medications causing fluid retention, baseline edema status, and recent ECG results 3, 5, 6

The American College of Cardiology recommends starting pioglitazone at 15-30 mg daily to minimize weight gain and edema, with gradual dose escalation only after several months with careful monitoring for weight gain, edema, or CHF exacerbation 4
Monitoring requirements include close observation for signs and symptoms of heart failure, particularly in the first 3 months of treatment, and instructing patients to report any new symptoms 3

Pioglitazone is associated with an increased risk of bone fractures, particularly in women, with a hazard ratio of 2.13 for fractures with rosiglitazone vs sulfonylurea, and exercise caution is recommended in patients with significant osteoporosis or fracture risk 1, 4, 7
Weight gain and edema are common side effects, with weight gain ranging from 0.9-2.6 kg with monotherapy doses of 15-45 mg daily 6
Pioglitazone is generally not recommended in chronic kidney disease due to fluid retention potential 4